BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gastrointestinal stromal tumor (GIST) is the most common soft tissue sarcoma.
• Understanding GIST molecular mechanisms is crucial for effective treatment and prevention.
• The specific role of BRD4 and tumor-associated macrophages (TAMs) in GIST progression remains largely unelucidated.

Purpose of the Study:

• To investigate the role of BRD4 in GIST progression.
• To explore the involvement of TAMs in the GIST tumor microenvironment.
• To identify potential therapeutic targets for GIST.

Main Methods:

• Analysis of BRD4 expression in GIST tissues and correlation with prognosis.
• In vitro and in vivo gain and loss of function studies to assess BRD4's impact on GIST growth and angiogenesis.
• Investigation of the molecular mechanism involving BRD4, CCL2, NF-κB signaling, and macrophage recruitment.

Main Results:

• BRD4 was found to be upregulated in GIST and associated with poorer prognosis.
• BRD4 significantly promoted GIST cell growth and angiogenesis both in vitro and in vivo.
• BRD4 enhances CCL2 expression via NF-κB activation, leading to macrophage recruitment and subsequent tumor growth.

Conclusions:

• BRD4 plays a critical role in promoting GIST progression and angiogenesis.
• BRD4-induced CCL2 expression and subsequent macrophage recruitment are key mechanisms in GIST.
• BRD4 represents a promising therapeutic target for GIST treatment.